Brain Disorders and Novel Therapeutics
Author(s) -
Hanns Möhler
Publication year - 2004
Publication title -
chimia international journal for chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 55
eISSN - 2673-2424
pISSN - 0009-4293
DOI - 10.2533/000942904777677461
Subject(s) - neuroscience , schizophrenia (object oriented programming) , gabaergic , gabaa receptor , inhibitory postsynaptic potential , neurotransmission , anxiety , biology , psychology , medicine , receptor , psychiatry , genetics
Using the power of genetic intervention, a strategy is illustrated which permits new insights into the pathobiology of brain diseases and the discovery of new therapeutic strategies. Brain function is based on a delicate balance between excitory and inhibitory neurotransmission. Selective circuits of GABAergic inhibitory transmission were targeted by introducing point mutations in defined GABAA receptor subtype genes in mice (knock-in strategy). New behavioural phenotypes were generated which reflect various brain disorders. In addition, novel drug targets were identified for the treatment of anxiety disorders, sleep disturbances, memory deficits, and schizophrenia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom